Latest & greatest articles for parkinson

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on parkinson or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on parkinson and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for parkinson

1. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study

Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study Apomorphine Sublingual Film for Off Episodes in Parkinson's Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features (...) a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Lancet Neurol Actions 2019 Dec 6 [Online ahead of print] Apomorphine Sublingual Film for Off Episodes in Parkinson's Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 3 Study , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborator CTH-300 Study investigators

2020 EvidenceUpdates

2. Cortical thickness in Parkinson's disease: a coordinate-based meta-analysis

Cortical thickness in Parkinson's disease: a coordinate-based meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2020 PROSPERO

3. Effect of non-drug therapy on fatigue and daytime sleepiness in Parkinson's disease: a systematic review and meta-analysis

Effect of non-drug therapy on fatigue and daytime sleepiness in Parkinson's disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

4. Effects of treadmill exercise on neuronal mitochondria in animal models of Parkinson's disease: A systematic review.

Effects of treadmill exercise on neuronal mitochondria in animal models of Parkinson's disease: A systematic review. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2020 PROSPERO

5. Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. Full Text available with Trip Pro

Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. Neurogenic orthostatic hypotension (nOH) is associated with neurodegenerative conditions, may cause symptoms of end-organ hypoperfusion, increases fall risk, and can negatively impact quality of life. Droxidopa is approved for the treatment of symptomatic nOH in adults. As the largest subpopulation of patients with nOH has a diagnosis of Parkinson disease (PD

2019 Movement disorders clinical practice Controlled trial quality: uncertain

6. Assessment of an Objective Method of Dyskinesia Measurement in Parkinson's Disease. Full Text available with Trip Pro

Assessment of an Objective Method of Dyskinesia Measurement in Parkinson's Disease. The goal of this study was to validate an objective method of measuring levodopa induced dyskinesia in Parkinson's disease (PD).To characterize agreement between the clinician-based measure and a force plate, we assessed dyskinesia in PD subjects participating in a randomized and blinded clinical trial of an adenosine A2A anatagonist. Convergent validity and intra-class correlations were evaluated between

2019 Movement disorders clinical practice Controlled trial quality: uncertain

7. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial (Abstract)

Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial High-intensity aerobic exercise might attenuate the symptoms of Parkinson's disease, but high-quality evidence is scarce. Moreover, long-term adherence remains challenging. We aimed to evaluate the effectiveness of aerobic exercise-gamified and delivered at home, to promote adherence-on relieving motor symptoms in patients with Parkinson's disease with mild (...) disease severity who were on common treatment regimes.In this single-centre, double-blind, randomised controlled trial (Park-in-Shape), we recruited sedentary patients with Parkinson's disease from the outpatient clinic at Radboudumc, Nijmegen, Netherlands. Patients were made aware of the study either by their treating neurologist or via information in the waiting room. Patients could also contact the study team via social media. We included patients aged 30-75 years with a Hoehn and Yahr stage of 2

2019 EvidenceUpdates

8. Istradefylline (Nourianz) - Parkinson's disease

Istradefylline (Nourianz) - Parkinson's disease CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022075Orig1s000 CLINICAL REVIEW(S) (b) (4) Clinical Review Natalie Branagan, MD NDA 022075 Nourianz/istradefylline CLINICAL REVIEW Application Type NDA Application Number(s) 022075 Priority or Standard Class 2 Resubmission Submit Date(s) February 27, 2019 Received Date(s) February 27, 2019 PDUFA Goal Date August 27, 2019 Division/Office DNP Reviewer Name(s) Natalie Branagan, MD Review (...) Completion Date August 26, 2019 Established/Proper Name Istradefylline (Proposed) Trade Name Nourianz Applicant Kyowa Kirin Inc Dosage Form(s) Tablets Applicant Proposed Dosing Administer 20 mg orally once daily. The dose may be increased Regimen(s) to 40 mg once daily based on Applicant Proposed Adjunctive treatment to levodopa/carbidopa in adult patients Indication(s)/Population(s) with Parkinson’s disease experiencing “OFF” episodes. Recommendation on There do not appear to be safety concerns

2019 FDA - Drug Approval Package

9. Levodopa (Inbrija) - Parkinson’s disease

Levodopa (Inbrija) - Parkinson’s disease Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/452546/2019 EMEA/H/C/004786 Inbrija (levodopa) An overview of Inbrija and why (...) it is authorised in the EU What is Inbrija and what is it used for? Inbrija is a medicine used to treat adults with Parkinson’s disease (a progressive brain disease that causes shaking and muscle stiffness and slows movement). Inbrija is used to treat symptoms during ‘off’ periods (times when the patient has more difficulty moving about) that occur while the patient is taking their usual treatment of a combination of levodopa and an inhibitor of dopa-decarboxylase. Inbrija contains the active substance

2019 European Medicines Agency - EPARs

10. Canadian guideline for Parkinson disease

Canadian guideline for Parkinson disease APPENDIX 1: CANADIAN GUIDELINE FOR PARKINSON DISEASE, 2 ND EDITION www.parkinson.ca www.ParkinsonClinicalGuidelines.ca Parkinson-final-E.indd 1 2019-09-05 2:39 PMNote: This full version of the Canadian Guideline for Parkinson Disease has been copyedited to be consistent with the summary article published in CMAJ, but has not been peer reviewed. English printed: 978-1-897490-48-8 English electronic: 978-1-897490-49-5 Parkinson-final-E.indd 2 2019-09-05 2 (...) :39 PMTABLE OF CONTENTS Parkinson-final-E.indd 3 2019-09-05 2:39 PMINTRODUCTION ________________ 6 COMMUNICATION ____________ 12 DIAGNOSIS AND PROGRESSION _______________ 15 TREATMENT _________________ 19 NONMOTOR FEATURES OF PARKINSON DISEASE _______ 28 PALLIATIVE CARE _____________ 36 SUPPLEMENTAL MATERIAL _____ 38 REFERENCES _________________ 51 COMMUNICATION n People with Parkinson disease should be encouraged to participate in choices about their own care. n Communication should be in verbal

2019 CPG Infobase

11. Safinamide (Xadago) for the treatment of adult patients with idiopathic Parkinson's disease

Safinamide (Xadago) for the treatment of adult patients with idiopathic Parkinson's disease Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease | Report | National Health Care Institute You are here: Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease Search within English part of National Health Care Institute Search Safinamide (Xadago®) for the treatment of adult patients with idiopathic Parkinson's disease

2019 National Health Care Institute (Zorginstituut Nederland)

12. Safinamide (Onstryv) - idiopathic Parkinson's disease

Safinamide (Onstryv) - idiopathic Parkinson's disease Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2019 Health Canada - Drug and Health Product Register

13. Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease: A Randomized Controlled Trial Full Text available with Trip Pro

Land Plus Aquatic Therapy Versus Land-Based Rehabilitation Alone for the Treatment of Freezing of Gait in Parkinson Disease: A Randomized Controlled Trial Freezing of gait (FOG) is one of the most disabling symptoms of Parkinson disease (PD). Different land-based rehabilitation approaches based on motor and cognitive strategies can be effective in treating FOG. Although there are data about the efficacy of aquatic therapy in ameliorating this phenomenon, no study has explored the combined (...) effect of land-based therapies plus aquatic therapy in patients with PD who have FOG.The objective was to investigate the effectiveness of a multidisciplinary, intensive, motor-cognitive rehabilitation treatment (MIRT) in improving FOG and whether implementation with aquatic therapy (MIRT-AT) adds further benefits.The design consisted of a single-blind, parallel-group, 1:1 allocation ratio, randomized trial.The Department of Parkinson Disease, Movement Disorders and Brain Injury Rehabilitation

2019 EvidenceUpdates

14. Randomized trial of care management to improve Parkinson disease care quality (Abstract)

Randomized trial of care management to improve Parkinson disease care quality To test effects on care quality of Chronic Care Model-based Parkinson disease (PD) management.This 2-group stratified randomized trial involved 328 veterans with PD in southwestern United States. Guided care management, led by PD nurses, was compared to usual care. Primary outcomes were adherence to 18 PD care quality indicators. Secondary outcomes were patient-centered outcome measures. Data sources were telephone (...) of the changes over time was in the positive Patient Health Questionnaire-2 depression screen for intervention minus usual care (-11.52 [95% CI -20.42, -2.62]).A nurse-led chronic care management intervention, Care Coordination for Health Promotion and Activities in Parkinson's Disease (CHAPS), substantially increased adherence to PD quality of care indicators among veterans with PD, as documented in the EMR. Of 8 secondary outcomes assessed, a screening measure for depressive symptomatology was the only

2019 EvidenceUpdates

15. Aquatic exercise improves motor impairments in people with Parkinson`s disease, with similar or greater benefits than land-based exercise: a systematic review Full Text available with Trip Pro

Aquatic exercise improves motor impairments in people with Parkinson`s disease, with similar or greater benefits than land-based exercise: a systematic review What are the effects of aquatic exercise on disease severity, (non-)motor impairments, activity performance, fear of falling, and quality of life in people with Parkinson's disease (PD)? Does aquatic exercise have greater effects on these outcomes than other forms of exercise in people with PD?Systematic review and meta-analysis (...) in the Unified Parkinson's Disease Rating Scale Part III (MD -4.6, 95% CI -7.5 to -1.7) in favour of aquatic exercise. Six studies compared aquatic exercise with land-based exercise after intervention (mean 7.2 weeks of training (SD 2.2); 159 participants). The effect of aquatic exercise was superior to land-based exercise on the Berg Balance Scale (MD 2.7, 95% CI 1.6 to 3.9), the Falls Efficacy Scale (MD -4.0, 95% CI -6.1 to -1.8) and the 39-item Parkinson's Disease Questionnaire (MD -6.0, 95% CI -11.3

2019 EvidenceUpdates

16. Bright light therapy for depression in Parkinson disease: A randomized controlled trial (Abstract)

Bright light therapy for depression in Parkinson disease: A randomized controlled trial To assess the efficacy of bright light therapy (BLT) in reducing depressive symptoms in patients with Parkinson disease (PD) and major depressive disorder (MDD) compared to a control light.In this double-blind controlled trial, we randomized patients with PD and MDD to treatment with BLT (±10,000 lux) or a control light (±200 lux). Participants were treated for 3 months, followed by a 6-month naturalistic

2019 EvidenceUpdates

17. Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study (Abstract)

Comparative Effectiveness of mHealth-Supported Exercise Compared With Exercise Alone for People With Parkinson Disease: Randomized Controlled Pilot Study Declining physical activity commonly occurs in people with Parkinson disease (PD) and contributes to reduced functional capacity and quality of life.The purpose of this study was to explore the preliminary effectiveness, safety, and acceptability of a mobile health (mHealth)-mediated exercise program designed to promote sustained physical (...) . Daily steps and moderate-intensity minutes were measured using a step activity monitor for 1 week at baseline and again at 12 months. Secondary outcomes included the 6-Minute Walk Test, Parkinson Disease Questionnaire 39 mobility domain, safety, acceptability, and adherence.Both groups increased daily steps, moderate-intensity minutes, and 6-Minute Walk Test, with no statistically significant between-group differences observed. In the less active subgroup, changes in daily steps and moderate

2019 EvidenceUpdates

18. Trunk Exercises Improve Gait Symmetry in Parkinson Disease: A Blind Phase II Randomized Controlled Trial. (Abstract)

Trunk Exercises Improve Gait Symmetry in Parkinson Disease: A Blind Phase II Randomized Controlled Trial. Deficits in step-to-step symmetry and trunk muscle activations have been linked to falls in Parkinson disease. Given such symptoms are poorly managed with anti-parkinsonian medications, alternate therapies are needed. This blind phase II randomized controlled trial sought to establish whether exercise can improve step-to-step symmetry in Parkinson disease.Twenty-four Parkinson disease (...) , active interventions seem more suited to increasing independence and quality of life for people with Parkinson disease.Complete the self-assessment activity and evaluation online at http://www.physiatry.org/JournalCME CME OBJECTIVES: Upon completion of this article, the reader should be able to do the following: (1) Describe the effect deficits in trunk muscle function have on gait in individuals with Parkinson disease; (2) Identify the benefits of targeted trunk exercises on step-to-step symmetry

2019 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

19. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson`s disease: a randomised, double-blind, placebo-controlled phase 3 trial (Abstract)

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson`s disease: a randomised, double-blind, placebo-controlled phase 3 trial Patients with Parkinson's disease chronically treated with levodopa commonly have delayed or unpredictable onset of its benefits after oral intake. In this study, we assessed the safety and efficacy of CVT-301, a self-administered levodopa oral inhalation powder, for the treatment of patients (...) with Parkinson's disease during off periods.In this randomised, double-blind, placebo-controlled, phase 3 trial, patients were recruited at 65 sites in Canada, Poland, Spain, and the USA. Eligible participants were patients with Parkinson's disease aged 30-85 years, who had daily off periods of 2 h or longer and showed an improvement of 25% or greater in the Unified Parkinson's Disease Rating Scale (UPDRS) motor score from off to on state after use of an oral levodopa plus a dopa-decarboxylase inhibitor

2019 EvidenceUpdates

20. Path Finder for freezing of gait in people with Parkinson?s disease

Path Finder for freezing of gait in people with Parkinson?s disease P Path Finder for freezing of gait in people with ath Finder for freezing of gait in people with P Parkinson arkinson’s disease ’s disease Medtech innovation briefing Published: 25 January 2019 nice.org.uk/guidance/mib170 pathways Summary Summary The technology technology described in this briefing is Path Finder laser shoe attachment. It is used as a walking aid and is designed to help prevent freezing of gait in people (...) with Parkinson's disease. The inno innovativ vative aspects e aspects are that it is currently the only hands-free visual-cueing device for people with Parkinson's disease available in the UK. The intended place in ther place in therap apy y would be in place of other visual-cue walking aids but together with a reduced number of physiotherapy sessions, depending on the individuals' disease stage and personal preference. It would be used by the patient in their home or in the physiotherapy clinic. It may also

2019 National Institute for Health and Clinical Excellence - Advice